Entyvio Outperforms Anti-TNF Alpha Therapies in Real-world Bowel Disease Studies

Entyvio Outperforms Anti-TNF Alpha Therapies in Real-world Bowel Disease Studies
Real-world treatment results showed that  Takeda's Entyvio (vedolizumab) was better than an anti-tumor necrosis factor-alpha therapy at alleviating moderate to severe ulcerative colitis or Crohn's disease, according to several studies. They showed that Entyvio, a biologic, did a better job than anti-TNF-alpha therapy at  healing the mucus that lines intestines and of achieving endoscopic remission — an end to inflammation that a doctor can spot with a scope. Researchers presented the studies at the 13th Congress of the European Crohn's and Colitis Organization in Vienna, Feb. 14-17. In one study, the U.S. Victory consortium compared Entyvio and anti-TNF-alpha's ability to treat 334 ulce
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *